|
Eculizumab treatment of paroxysmal nocturnal hemoglobinuria presenting as moyamoya syndrome in a 9-year-old male.
|
Jan 2012
|
Pediatr Blood Cancer
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria
|
Apr 2012
|
BioDrugs
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia
|
Mar 2017
|
Haematologica
|
aplastic anemia
|
|
Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes
|
Nov 2014
|
Medicare Medicaid Res Rev
|
myelodysplastic syndromes (MDS)
|
|
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion
|
Dec 2015
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia.
|
Oct 2013
|
Am J Hematol
|
aplastic anemia
|
|
Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series
|
Jan 2021
|
Annals of Hematology
|
aplastic anemia
|
|
Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
|
Sep 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
|
May 2016
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry
|
Jan 2019
|
Am J Hematol
|
aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH)
|
